Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $19 to $18.
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $17 to $21.
Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $16 to $19.
Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the price target from $18 to $21.
Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...
On August 29, 2025, Dawn Farrell, Chair of the Board of Directors (the "Board") of The Chemours Company (the "Compa...
